Type 2 Diabetes Mellitus
Conditions
Brief summary
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of MK1006
Interventions
DRUGMK1006
MK1006 capsules: 1 mg, 10 mg, and 20 mg. Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg. Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg. There will a 7-day interval between each dose
DRUGPlacebo
Placebo capsule to match MK1006 1, 10, and 20 mg. Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg. Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg. There will a 7-day interval between each dose
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Participant is between 18 and 55 years of age. Participants up to 65 years of age may be enrolled in Panels B and C * Female participants must be postmenopausal or otherwise unable to have children * Participant has a body mass index (BMI) less than or equal to 42 kg/m\^2 at the screening visit * Participant has type 2 diabetes and is being treated with either diet and exercise or a single oral anti-hyperglycemic medication. For Panels B and C, participant may be treated with combination oral anti-hyperglycemic medications * Participant is willing to follow the American Heart Association (AHA) diet and exercise program throughout the study * Participant is a nonsmoker or has not used nicotine-containing products for 6 months prior to study start
Exclusion criteria
* Participant has a history of stroke, seizures, or other neurological disorders * Participant has a recent history of eye infection or other inflammatory eye conditions * Participant has glaucoma or is blind * Participant has had eye surgery within 6 months of study start (Lasik is permitted) * Participant has type 1 diabetes * Participant cannot stop taking any of their current prescription or non-prescription medications during the study * Participant consumes more than 3 alcoholic beverages per day * Participant consumes more than 6 caffeinated beverages per day * Participant has had major surgery or has donated blood within 4 weeks of study start * Participant has multiple and/or severe allergies to drugs or food
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) On Study | From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks) | An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience. |
| Number of Participants Who Discontinued Treatment Due to an AE | From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks) | An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | From pre-dose to 168 hours post-dose | — |
| Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | From pre-dose to 168 hours post-dose | The AUC(0-∞) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. |
| Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | From pre-dose to 168 hours post-dose | The AUC(0-24) was estimated by determining the total area under the curve of the concentration versus time curve to 24 hours post dose. |
| Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | From pre-dose to 168 hours post-dose | The apparent terminal half-life was defined as the time required for the plasma concentration of MK1006 to decrease 50% in the final stage of its elimination |
| Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | From pre-dose to 168 hours post-dose | — |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Participants Participants were treated with MK1006 or dose-matched placebo over 5 treatment periods. | 25 |
| Total | 25 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Continuous | 54.2 years STANDARD_DEVIATION 9.2 |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 2 / 6 | 3 / 6 | 3 / 6 | 2 / 12 | 2 / 6 | 1 / 6 | 1 / 6 | 5 / 12 | 1 / 6 | 3 / 6 | 2 / 6 | 3 / 4 | 2 / 6 | 12 / 24 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 12 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 12 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 4 | 0 / 6 | 0 / 24 |
Outcome results
Primary
Number of Participants Experiencing Adverse Events (AEs) On Study
An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience.
Time frame: From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks)
Population: All Participants as Treated (APaT) Population; All participants who received at least one dose of the investigational drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 15 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 2 participants |
| 30 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 3 participants |
| 45 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 3 participants |
| 60 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 2 participants |
| 80 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 2 participants |
| 100 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 1 participants |
| 120 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 1 participants |
| 140 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 5 participants |
| 170 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 1 participants |
| 200 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 3 participants |
| 230 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 2 participants |
| 260 mg MK1006 | Number of Participants Experiencing Adverse Events (AEs) On Study | 3 participants |
| 30 mg MK1006 [Fed State] | Number of Participants Experiencing Adverse Events (AEs) On Study | 2 participants |
| Placebo | Number of Participants Experiencing Adverse Events (AEs) On Study | 13 participants |
Primary
Number of Participants Who Discontinued Treatment Due to an AE
An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience.
Time frame: From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks)
Population: All Participants as Treated (APaT) Population; All participants who received at least one dose of the investigational drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 15 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 30 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 45 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 60 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 80 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 100 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 120 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 140 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 170 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 200 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 230 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 260 mg MK1006 | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| 30 mg MK1006 [Fed State] | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
| Placebo | Number of Participants Who Discontinued Treatment Due to an AE | 0 participants |
Secondary
Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose
The apparent terminal half-life was defined as the time required for the plasma concentration of MK1006 to decrease 50% in the final stage of its elimination
Time frame: From pre-dose to 168 hours post-dose
Population: Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 15 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 17.0 hr | Standard Deviation 3.1 |
| 30 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 17.3 hr | Standard Deviation 1.3 |
| 45 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 17.6 hr | Standard Deviation 3.5 |
| 60 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 18.3 hr | Standard Deviation 2.3 |
| 80 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 20.0 hr | Standard Deviation 1.4 |
| 100 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 23.0 hr | Standard Deviation 5.2 |
| 120 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 19.3 hr | Standard Deviation 4.7 |
| 140 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 25.7 hr | Standard Deviation 5.6 |
| 170 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 22.3 hr | Standard Deviation 5.6 |
| 200 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 22.8 hr | Standard Deviation 5 |
| 230 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 26.7 hr | Standard Deviation 2.6 |
| 260 mg MK1006 | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 31.3 hr | Standard Deviation 6.6 |
| 30 mg MK1006 [Fed State] | Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose | 19.2 hr | Standard Deviation 3.2 |
Secondary
Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006
The AUC(0-24) was estimated by determining the total area under the curve of the concentration versus time curve to 24 hours post dose.
Time frame: From pre-dose to 168 hours post-dose
Population: Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 15 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 468 nM.hr | Standard Deviation 101 |
| 30 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 1030 nM.hr | Standard Deviation 155 |
| 45 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 1520 nM.hr | Standard Deviation 416 |
| 60 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 2100 nM.hr | Standard Deviation 580 |
| 80 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 3450 nM.hr | Standard Deviation 1570 |
| 100 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 4930 nM.hr | Standard Deviation 2120 |
| 120 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 6110 nM.hr | Standard Deviation 1420 |
| 140 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 5690 nM.hr | Standard Deviation 2490 |
| 170 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 6590 nM.hr | Standard Deviation 3320 |
| 200 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 6270 nM.hr | Standard Deviation 4850 |
| 230 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 8810 nM.hr | Standard Deviation 3780 |
| 260 mg MK1006 | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 8500 nM.hr | Standard Deviation 4380 |
| 30 mg MK1006 [Fed State] | Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006 | 1060 nM.hr | Standard Deviation 232 |
Secondary
Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006
The AUC(0-∞) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.
Time frame: From pre-dose to 168 hours post-dose
Population: Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 15 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 595 nM.hr | Standard Deviation 106 |
| 30 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 1330 nM.hr | Standard Deviation 193 |
| 45 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 1900 nM.hr | Standard Deviation 464 |
| 60 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 2790 nM.hr | Standard Deviation 810 |
| 80 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 4380 nM.hr | Standard Deviation 1960 |
| 100 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 6360 nM.hr | Standard Deviation 2680 |
| 120 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 7670 nM.hr | Standard Deviation 1900 |
| 140 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 7500 nM.hr | Standard Deviation 2800 |
| 170 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 8160 nM.hr | Standard Deviation 3570 |
| 200 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 8440 nM.hr | Standard Deviation 5520 |
| 230 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 11670 nM.hr | Standard Deviation 4020 |
| 260 mg MK1006 | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 11460 nM.hr | Standard Deviation 5340 |
| 30 mg MK1006 [Fed State] | Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006 | 1380 nM.hr | Standard Deviation 271 |
Comparison: A linear mixed-effect model was used to estimate the geometric mean AUC (0-∞) for MK1006 at every dose level.Mixed-Effect Model
Secondary
Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose
Time frame: From pre-dose to 168 hours post-dose
Population: Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 15 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 60.0 nM | Standard Deviation 22.7 |
| 30 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 123.0 nM | Standard Deviation 27.7 |
| 45 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 191.0 nM | Standard Deviation 76.5 |
| 60 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 251.0 nM | Standard Deviation 73.4 |
| 80 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 434.0 nM | Standard Deviation 196 |
| 100 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 614.0 nM | Standard Deviation 267 |
| 120 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 783.0 nM | Standard Deviation 230 |
| 140 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 786.0 nM | — |
| 170 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 768.0 nM | Standard Deviation 364 |
| 200 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 738.0 nM | Standard Deviation 688 |
| 230 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 1174.0 nM | Standard Deviation 822 |
| 260 mg MK1006 | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 901.0 nM | Standard Deviation 508 |
| 30 mg MK1006 [Fed State] | Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose | 141.0 nM | Standard Deviation 37.4 |
Comparison: A linear mixed-effect model was used to estimate the geometric mean Cmax for MK1006 at every dose level.Mixed-effect Model
Secondary
Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose
Time frame: From pre-dose to 168 hours post-dose
Population: Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 15 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 1.5 hr |
| 30 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 2.0 hr |
| 45 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 3.0 hr |
| 60 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 3.0 hr |
| 80 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 3.0 hr |
| 100 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 3.0 hr |
| 120 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 4.0 hr |
| 140 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 3.0 hr |
| 170 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 3.5 hr |
| 200 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 5.0 hr |
| 230 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 4.0 hr |
| 260 mg MK1006 | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 4.5 hr |
| 30 mg MK1006 [Fed State] | Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose | 2.0 hr |